Current Report Filing (8-k)
May 19 2015 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2015
Adamas Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36399 |
|
42-1560076 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
of incorporation) |
|
|
|
|
1900 Powell Street, Suite 750 |
|
|
Emeryville, CA |
|
94608 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (510) 450-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 14, 2015, Adamas Pharmaceuticals, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting) at 1800 Powell Street, Emeryville, California 94608. Stockholders who owned the Companys common stock at the close of business on March 18, 2015, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 17,705,406 shares of the Companys common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 12,597,468 shares of the Companys common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Companys Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 30, 2015.
Proposal No. 1 Election of Directors
The Companys stockholders elected the Class I director nominees below to the Companys Board of Directors to hold office until the 2018 Annual Meeting of Stockholders or until their successors are elected.
Class I Director Nominees |
|
Votes For |
|
Votes Withheld |
|
Broker Non Votes |
|
William Ericson |
|
9,818,050 |
|
484,754 |
|
2,294,664 |
|
Martha Demski |
|
9,830,282 |
|
472,522 |
|
2,294,664 |
|
Ivan Lieberburg, M.D. Ph.D. |
|
9,830,132 |
|
472,672 |
|
2,294,664 |
|
Proposal No. 2 Ratification of Selection of Independent Registered Accounting Firm
The Companys stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2015.
Votes For |
|
Votes Against |
|
Abstentions |
|
12,551,016 |
|
32,009 |
|
14,443 |
|
Item 8.01 Other Events.
On May 18, 2015, Actavis plc. (Actavis) announced the launch in the United States of Namzaric (formerly known as MDX-8704), a fixed-dose combination product, which we co-developed and exclusively licensed to Forest Laboratories, LLC, a subsidiary of Actavis.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Adamas Pharmaceuticals, Inc. |
|
|
Dated: May 19, 2015 |
|
|
By: |
/s/ William J. Dawson |
|
|
William J. Dawson |
|
|
Chief Financial Officer |
3
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2023 to Aug 2024